Consistently, HCC cells with high BRI3BP expression showed greater sensitivity to small-molecule inhibitors—exemplified by lower IC50 values for lapatinib—than their low-expression counterparts. The gene discussed is BRI3BP; the disease is hepatocellular carcinoma.